Vascular Malformations- Pipeline Insight, 2024

Vascular Malformations- Pipeline Insight, 2024

DelveInsight’s, “Vascular Malformations- Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Vascular Malformations pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vascular Malformations: Understanding

Vascular Malformations: Overview

Vascular malformations are abnormal connections between blood or lymph vessels. They are typically present at birth (congenital) but may also develop during one’s lifetime. Vascular malformations are grouped together based upon their common embryological origin of having a single endothelial cell lining. Vascular malformations are thought to result from developmental errors during embryogenesis, such as abnormal signaling processes that control apoptosis, maturation, and growth of vascular cells. These errors lead to the persistence of vascular plexus cells with a certain degree of differentiation. There are four major categories of vascular malformations based on their flow characteristics: slow-flow (capillary malformation, venous malformation, lymphatic malformation) and fast-flow (arteriovenous malformation). Symptoms of vascular malformations depend on their size and location. The most common symptoms include: Pain Swelling, skin discoloration color in the area of the malformation. Some people with high-flow vascular malformations can become short of breath and tire easily during activities. The skin over a vascular malformation may be warm and discolored. In addition, skin could: Become tender, bleed, bruise easily and break down. For venous malformations, although surgery is sometimes useful, it is usually difficult for surgeons to completely remove vascular malformations, which will return if not removed completely. A nonsurgical method of closing down the blood or lymph flow into the malformation is done by interventional radiologists, who treat patients with image guided procedures. Vascular malformations are treated by embolization. The AVMs and hemangiomas can be closed by advancing a tiny plastic tubing, no larger than a pencil point, into the feeding artery to the malformation. This can be done without incisions or stitches, and with only mild sedation. Medical glue or alcohol or small beads are then floated into the malformation until it is full and no longer has blood flowing through it. For Pulmonary AVMs platinum coils are used to block flow through the feeding artery to the malformation. The VMs and LMs are closed by injecting alcohol into the sacs filled with venous blood or lymph until these sacs collapse and no longer fill. The arteriovenous malformations can be treated with a one-night hospital stay. There is usually minimal discomfort for one to three days. The venous and lymphatic malformations also require one night in the hospital. These malformations swell after treatment with alcohol, and the swelling and pain may last for three to five days. During this time, patients medication are given for any pain or swelling they may have. The full shrinkage of these malformations may take four to six weeks.

""Vascular Malformations- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Malformations pipeline landscape is provided which includes the disease overview and Vascular Malformations treatment guidelines. The assessment part of the report embraces, in depth Vascular Malformations commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Malformations collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Malformations R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Malformations.

Vascular Malformations Emerging Drugs Chapters

This segment of the Vascular Malformations report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vascular Malformations Emerging Drugs

• VT 30: Venthera

VT 30, is a novel investigational therapy is designed to target the genetic drivers of venous (VM), lymphatic (LM), and venolymphatic malformations (VLM) at their source by delivering a potent PI3Kα inhibitor directly to affected tissue. The majority of these cutaneous vascular malformations are driven by somatic mutations in the PIK3CA and TEK genes. These mutations result in overactivation of the PI3K pathway and have been identified as the root cause of the vast majority of VMs, LMs, and VLMs. Because BBP-681 is applied directly to skin lesions, it may minimize complications seen with systemic treatments.

• NPC-12: Nobelpharma

NPC-12, is an investigational drug being developed by Nobelpharma.It is acts as a T lymphocyte inhibitor. Currently, the drug is being evaluated at Phase III for the treatment of vascular anomalies.

Further product details are provided in the report……..

Vascular Malformations: Therapeutic Assessment

This segment of the report provides insights about the different Vascular Malformations drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Vascular Malformations

There are approx. 8+ key companies which are developing the therapies for Vascular Malformations. The companies which have their Vascular Malformations drug candidates in the most advanced stage, i.e. Phase III, Nobelpharma.

• Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Vascular Malformations pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vascular Malformations: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Malformations therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Malformations drugs.

Vascular Malformations Report Insights

• Vascular Malformations Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vascular Malformations Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vascular Malformations drugs?
• How many Vascular Malformations drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Malformations?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Malformations therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vascular Malformations and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Nobelpharma
• Venthera
• ONY Biotech
• Vaderis Therapeutics
• BridgeBio Pharma
• Genentech, Inc.

Key Products

• VT 30
• NPC-12
• VAD 044
• Acellular Tissue Engineered Vessels (ATEV)
• Cobimetinib